Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer
Conclusions
We conclude that an intermediate-duration IL delivery of multiple doses of immunotherapeutic factors using implantable delivery ports is feasible, highly-tolerable and can be reproducibly performed in cancer patients to administer immune cells, or potentially, other immune factors. However, long-term IL port placement (>7.5 weeks), is not a currently-feasible option.
Trial registration
NCT00558051, registered Nov. 13, 2007.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cellulitis | Colorectal Cancer | Immunotherapy | Ultrasound | Vaccines